Evidence map›Paper›PMID 41303362›Full record

ReviewInternational journal of molecular sciences2025

Beyond Rodents: Alternative Animal Models in Colorectal Cancer Research.

Wei Xiong, Solène Favier, Ting Wu, Frédérique Ponce, Charles Dumontet, Marie Alexandra Albaret, Frédéric Hollande, Jean-Jacques Diaz, Hichem C Mertani

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. International journal of molecular sciences · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei XiongLabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, CEDEX 08, 69008 Lyon, France.
Solène FavierLabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, CEDEX 08, 69008 Lyon, France.
Ting WuLabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, CEDEX 08, 69008 Lyon, France.
Frédérique PonceService de Cancérologie, UR ICE, VetAgro Sup, Université de Lyon, 69280 Marcy-l'Étoile, France.ORCID 0000-0003-0741-0654
Charles DumontetLabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, CEDEX 08, 69008 Lyon, France.
Marie Alexandra AlbaretLabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, CEDEX 08, 69008 Lyon, France.ORCID 0000-0003-3374-5298
Frédéric HollandePlasticity, Heterogeneity and Tumour Microenvironment International Research (PHANTOM) Laboratory, Centre National de la Recherche Scientifique (CNRS) and The University of Melbourne, Melbourne, VIC 3000, Australia.ORCID 0000-0002-7046-8392
Jean-Jacques DiazLabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, CEDEX 08, 69008 Lyon, France.
Hichem C MertaniLabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Centre Léon Bérard, Université Claude Bernard Lyon 1, Université de Lyon, CEDEX 08, 69008 Lyon, France.ORCID 0000-0002-5958-6662

Funding

European network COST Translacore (COST Action) CA21154
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide, imposing a significant burden on public health. Despite the use of various therapeutic strategies, the prognosis for patients with metastatic and drug-resistant CRC remains poor, which underscores the need for further investigations into cancer mechanisms to develop more effective treatments. Rodents, particularly mice, are the most frequently used animal models for CRC research. However, as the demand for more precise simulations and higher ethical standards in animal experimentation grows, the applicability of rodent models may face increasing limitations. This review highlights a variety of non-rodent animals, including model organisms such as zebrafish (

Indexed as

Colorectal NeoplasmsDisease Models, AnimalAnimalsCaenorhabditis elegansDogsHumansMiceRabbitsZebrafishchorioallantoic membrane modelcolorectal cancerdrug resistancemammalsmodel organismsnonrodent animalstranslational research

Identifiers

PMID41303362
PMCPMC12652637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.